Q32 Bio公布Bempikibart斑秃2a期36周积极顶线数据

Q32 Bio Inc. (QTTB), a clinical-stage biotechnology company announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial evaluating Bempikibart in patients with severe or very severe alopecia areata (AA).
Trial Design
The SIGNAL-AA study is a randomized, double-blind, placebo-controlled Phase 2a trial conducted in two parts. The Part A was a 12-week proof-of-concept study, while Part B extended treatment to 36 weeks to assess durability of response and long-term safety. Patients were stratified by prior JAK inhibitor exposure, allowing evaluation of efficacy in both treatment-naïve and previously treated populations.
Key Findings
The trial met its primary endpoint, showing a mean percent reduction in SALT score of 35.3% from baseline in the modified intent-to-treat (mITT) analysis. At Week 36, 40% of patients achieved a SALT-20 response in the mITT group, while 30.3% achieved SALT-20 in the intent-to-treat (IIT) analysis of all enrolled patients.
Bempikibart was generally well tolerated, with a safety profile consistent with prior studies and no new safety signals. The therapy also demonstrated favorable pharmacokinetic, pharmacodynamic, and anti-drug antibody characteristics.
Expert Commentary
"Alopecia areata is a complex, immune-driven disease with limited therapeutic options. The robust efficacy data in a population that includes JAK inhibitor-experienced patients, combined with a differentiated safety profile, demonstrate the potential for bempikibart to be a first-line treatment" said Arash Mostaghimi, of Brigham and Women's Hospital, Harvard Medical School.
Q32 Bio's CEO Jodie Morrison added, "These results highlight the opportunity to deliver a differentiated, targeted treatment option for patients who remain in need of an effective, safe, and more durable alternative to JAK inhibitors."
Next Steps
The company intends to advance Bempikibart into a registration-directed program in the first half of 2027, building on the SIGNAL-AA findings.
QTTB has traded between $1.57 and $15.02 over the past year. The stock closed Friday's trading (July 10, 2026) at $11.21, down 10.96%. In pre-market trading the stock is at $20.20, up 80.20%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 03, 2026 16:09 ET A busy week for economic data saw the release of several reports on the labor market and the manufacturing sector. In the U.S., the jobs report for June was in focus and results of the latest ISM purchasing managers’ survey threw light on the health of the factory sector. In Europe, results of the PMI surveys gained attention while the unemployment figures from Germany were also in news. Similarly in Asia, survey data on the Chinese manufacturing sector was the highlight.